Anixa Biosciences
Quarterly Financials
| Values in thousands | 2024-07-31 | 2024-04-30 | 2024-01-31 | 2023-10-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $156 |
Gross Profit | -3 | -12 | -13 | 144 |
EBITDA | -3,589 | -3,467 | -3,609 | -2,709 |
EBIT | -3,592 | -3,479 | -3,622 | -2,721 |
Net Income | -3,277 | -3,139 | -3,255 | -2,690 |
Net Change In Cash | 0 | 0 | 0 | 156 |
Free Cash Flow | -2,643 | -1,456 | -2,309 | -1,969 |
Cash | 1,225 | 995 | 998 | 915 |
Basic Shares | 32,054 | 31,914 | 31,446 | 31,083 |
Annual Financials
| Values in thousands | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 |
|---|---|---|---|---|
Revenue | $210 | $2,469,000 | $512 | $0 |
Gross Profit | 49 | 2,468,958 | 127 | -90 |
EBITDA | -10,965 | -13,729 | -13,081 | -10,002 |
EBIT | -11,011 | -13,771 | -13,141 | -10,092 |
Net Income | -9,811 | -13,491 | -12,946 | -10,132 |
Net Change In Cash | 210 | 2,469,000 | 512 | 0 |
Cost of Revenue | -16,768 | 2,925 | ||
Free Cash Flow | -6,209 | -6,492 | -4,936 | -6,191 |
Cash | 915 | 12,360 | 29,128 | 6,417 |
Basic Shares | 30,980 | 30,374 | 28,578 | 22,229 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-07-31 | -$0.10 |
2024-04-30 | -$0.10 |
2024-01-31 | -$0.10 |
2023-10-31 | -$0.09 |
